Literature DB >> 639687

[Treatment of acute myocardial infarction with metoprolol (author's transl)].

A Wirtzfeld, G Klein, W Delius, D Sack.   

Abstract

Metoprolol, a cardioselective beta-receptor blocker, was administered to 12 patients three to ten hours after sustaining a transmural myocardial infarction, and the effect of the drug (10 mg i.v., followed by 50 mg orally every eight hours) was followed for 48 hours. Heart rate decreased by 16% and cardiac output by 27%, while blood pressure and stroke volume decreased little and pulmonary "wedge" pressure was not significantly changed. Even in patients with initially definitely elevated left-ventricular filling pressure (greater than 20 mm Hg) the drug was well tolerated without any further rise in pressure. Since left-ventricular work was significantly decreased (stroke work--15%, cardiac output--31%) and the duration of diastole, decisive for coronary perfusion, was prolonged, it is concluded that early administration of beta-receptor blockers has a favourable effect on myocardial oxygenation and possibly reduce ultimate infarct size.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 639687     DOI: 10.1055/s-0028-1104477

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Haemodynamic dose-response effects of i.v. metoprolol in coronary heart disease.

Authors:  W G Hendry; B Silke; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  Apparent superiority of H2-receptor stimulation and simultaneous beta-blockade over conventional treatment with beta-sympathomimetic drugs in post-acute myocardial infarction: cardiac effects of impromidine--a new specific H2-receptor agonist-in the surviving catecholamine-insensitive myocardium.

Authors:  G Baumann; S B Felix; C D Heidecke; G Riess; U Loher; L Ludwig; H Blömer
Journal:  Agents Actions       Date:  1984-10

3.  Limitation of myocardial infarct size in patients less than 66 years treated with alprenolol.

Authors:  J H Jürgensen; J Frederiksen; D A Hansen; O Pedersen-Bjergaard
Journal:  Br Heart J       Date:  1981-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.